Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
32 hedge funds and large institutions have $61.1M invested in Ibere Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$6.05M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.35M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.87M |
| 4 |
LA
Linden Advisors
New York
|
+$4.38M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$4.38M |
Top Sellers
IBER Hedge Fund Activity: Q2 2021 in Review
32 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q2 2021, worth a combined $61.1M.
Buyers outnumbered sellers: 32 funds opened new IBER positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $6.05M.
- 32 institutional investors held Ibere Pharmaceuticals (IBER) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $61.1M of Ibere Pharmaceuticals stock for Q2 2021.
- 32 funds opened new Ibere Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +32 holders.
- The largest Ibere Pharmaceuticals buyer in Q2 2021 was Hudson Bay Capital Management, an estimated $6.05M added.
Based on aggregated 13F filings for Q2 2021.